Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies to Invest $18 Million in Facility Expansion and Current GMP Compliance Plan

Published: Tuesday, April 02, 2013
Last Updated: Tuesday, April 02, 2013
Bookmark and Share
Project aims to broaden product offerings to growing diagnostics and pharmaceutical customer base.

Life Technologies Corporation announces plans to invest $18 million in a multi-phase plan to expand its facility in Pleasanton, Calif., where it will implement Current Good Manufacturing Practice (cGMP) capabilities for its genetic analysis products. The project, which executes against Life's roadmap to broaden its offerings in the growing molecular diagnostics market, will break ground in the second quarter of 2013. The expanded facility will provide accessibility for customers on a global scale and enable more efficient business continuity planning.

"As a provider of molecular companion diagnostic development and testing for the pharmaceutical and biotech industries, it is paramount that we have access to trustworthy oligos products that meet GMP compliance," said Byung-in Lee, Ph.D., MBA, Senior Director, Research & Development for AltheaDx. "Reagents such as those planned in Life Technologies' new manufacturing facility are essential for meeting regulatory requirements and will help speed up our companion diagnostic development and validation process."

The Pleasanton facility currently manufactures TaqMan® assays, GeneArt® and Ion AmpliSeq™ product lines and other widely used reagents that are part of Life Technologies' genetic analysis portfolio. The first phase of the project will repurpose 10,000 square feet of space to manufacture molecular probes and primers under cGMP standards. Subsequent phased expansions totaling an additional 30,000 square feet will follow over the next one-to-three years to produce regulatory-compliant materials for qPCR workflows in the clinical space.

"We are committed to providing the highest quality products that help meet the specific needs of our growing diagnostic and pharmaceutical customer base," said Mark Stevenson, President and COO of Life Technologies. "The expansion of our Pleasanton facility and plan to achieve cGMP certification underscores our growth strategy in new markets and our commitment to win in genetic analysis from discovery to diagnostics."

Products manufactured in cGMP-certified facilities ensure their quality meets standards of control for use in the pharmaceutical and medical fields. Life Technologies currently has nine facilities that follow cGMP standards and are ISO 9001/13485-compliant for the manufacture of a broad spectrum of products, including instruments, various reagents, assays, cell culture media and sera.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Acquisition Approved by Life Technologies Stockholders
Company announced that its stockholders voted to adopt the previously announced merger agreement.
Thursday, August 22, 2013
Life Technologies to Collaborate with Merck Serono
Long-term collaboration is aimed at developing, obtaining regulatory approval and commercializing companion diagnostics for selected Merck Serono drug development programs.
Wednesday, July 17, 2013
Life Technologies Screening Technology Receives Emergency Use Authorization
Life Technologies supports global effort to help accelerate emergency screening of Novel Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Wednesday, June 26, 2013
Life Technologies Acquires KDR Biotech
The acquisition is part of Life Technologies strategic international growth plan in fast-growing markets.
Friday, April 12, 2013
Life Technologies Announces Fourth Quarter and Fiscal 2012 Results
Fourth quarter revenue increased 3% to $999 million, or 4.5% excluding currency.
Tuesday, February 12, 2013
Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Products
Life's Applied Biosystems Dx Genetic Analyzer and SeCore® kits constitute first sequence-based system cleared for HLA typing.
Tuesday, February 12, 2013
JAMA Study Demonstrates Efficacy of Life Technologies' Lung Cancer Test
Genetic test identifies patients at high risk for mortality in the earliest stage of lung cancer. Study suggests test could maximize the benefits of early screening if used in combination with computed tomography.
Thursday, November 08, 2012
Life Technologies Announces Third Quarter 2012 Results
Revenue for the third quarter was $911 million, a decrease of 1.9 percent over the $929 million reported for the third quarter of 2011. Excluding the impact of currency, revenue growth for the quarter was 1.4 percent compared to the same period of the prior year.
Monday, November 05, 2012
VelaDx Signs Agreement with Life Technologies to Develop IVD Tests on Ion PGM Sequencer
Semiconductor sequencing brings unprecedented power to diagnostic tests to transform personalized medicine.
Wednesday, October 10, 2012
Life Technologies Acquires Compendia Bioscience
Bioinformatics expertise will enable deeper engagement with established customer base of leading pharmaceutical companies.
Tuesday, October 09, 2012
Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing
Life and Southern African Treatment and Resistance Network (SATuRN) partner in sequencing-based surveillance of drug resistance,in order to increases access in Africa.
Tuesday, July 24, 2012
Acquisition of Navigenics Expands Life Technologies' Capabilities
Addition of Navigenics' physician portal provides informatics to support patient management.
Thursday, July 19, 2012
Acquisition of Navigenics Expands Life Technologies' Capabilities in Diagnostics
CLIA-certified laboratory enables life technologies to launch lab-developed tests and expand partnership program in companion diagnostics.
Wednesday, July 18, 2012
Life Technologies to Accelerate Development of Ion Torrent Semiconductor Technology
Company to accelerate technology for a broad set of proteomic and antibody-based applications after passing internal Life Technologies R&D milestones.
Thursday, July 12, 2012
Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
The agreement will form Life Technologies DaAn Diagnostics, a joint venture diagnostics business in China. The move is expected to contribute to the early diagnosis of oncology, infectious diseases and genetic diseases.
Tuesday, January 17, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Genetic Test Could Improve Blood Cancer Treatment
Testing for genetic risk factors could improve treatment for myeloma – a cancer of the blood and bone marrow – by helping doctors identify patients at risk of developing more aggressive disease.
PTR-MS Breath Test Shows Potential for Detecting Liver Disease
Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!